Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SMALLPOX TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SMALLPOX TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SMALLPOX TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 CONVENTIONAL VACCINE – DRYVAX
5.2 OTHERS
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 REGULATORY FRAMEWORK
9 PIPELINE ANALYSIS
9.1 OVERVIEW
9.2 PHASE III CANDIDATES
9.3 PHASE II CANDIDATES
9.4 PHASE I CANDIDATES
9.5 OTHERS
10 IMPACT OF COVID-19 PANDEMIC ON THE MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 GLOBAL SMALLPOX TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 VACCINE(PREVENTION)
11.2.1 CONVENTIONAL VACCINE
11.2.1.1. APSV
11.2.1.2. OTHERS
11.2.2 TISSUE CULTURE BASED, LIVE VIRUS VACCINES
11.2.2.1. ACAM1000
11.2.2.2. ACAM2000
11.2.2.3. OTHERS
11.2.3 REPLICATION COMPETENT, ATTENUATED VACCINES
11.2.3.1. MVA-BN
11.2.3.2. VACCINIA
11.2.3.3. NYVAC
11.2.3.4. IMVAMUNE
11.2.4 SUBUNIT VACCINES
11.2.4.1. PROTEIN
11.2.4.2. DNA
11.2.4.3. OTHERS
11.3 ANTIVIRAL DRUGS (CURE)
11.3.1.1. TECOVIRIMAT
11.3.1.2. BRINCIDOFOVIR
11.3.1.3. CIDOFOVIR
11.3.1.4. OTHERS
12 GLOBAL SMALLPOX TREATMENT MARKET, BY PRODUCT TYPE
12.1.1 OVERVIEW
12.1.2 MONOVALENT
12.1.3 MULTIVALENT
13 GLOBAL SMALLPOX TREATMENT MARKET, BY STRAIN TYPE
13.1 OVERVIEW
13.2 NYCBOH
13.3 LISTER
13.4 ANKARA
13.5 COPENHAGEN
13.6 MVA
13.7 VACV
13.8 VARV
14 GLOBAL SMALLPOX TREATMENT MARKET, BY AGE GROUP
14.1 OVERVIEW
14.2 PAEDIATRIC
14.3 ADULTS
14.4 GERIATRICS
15 GLOBAL SMALLPOX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.3 INJECTABLES
15.3.1 SC
15.3.2 IM
15.3.3 IC
15.3.4 IP
15.4 OTHERS
16 GLOBAL SMALLPOX TREATMENT MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 GOVERNMENT
16.2.2 PRIVATE
16.3 HOMECARE
16.4 SPECIALTY CLINICS
16.5 OTHERS.
17 GLOBAL SMALLPOX TREATMENT MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 RETAIL SALES
17.3.1 ONLINE STORES
17.3.2 PHARMACY STORES
17.3.3 OTHERS
17.4 OTHERS
18 GLOBAL SMALLPOX TREATMENT MARKET, BY GEOGRAPHY
Global Smallpox treatment market, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1.1 NORTH AMERICA
18.1.1.1. U.S.
18.1.1.2. CANADA
18.1.1.3. MEXICO
18.1.2 EUROPE
18.1.2.1. GERMANY
18.1.2.2. FRANCE
18.1.2.3. U.K.
18.1.2.4. HUNGARY
18.1.2.5. LITHUANIA
18.1.2.6. AUSTRIA
18.1.2.7. IRELAND
18.1.2.8. NORWAY
18.1.2.9. POLAND
18.1.2.10. ITALY
18.1.2.11. SPAIN
18.1.2.12. RUSSIA
18.1.2.13. TURKEY
18.1.2.14. BELGIUM
18.1.2.15. NETHERLANDS
18.1.2.16. SWITZERLAND
18.1.2.17. REST OF EUROPE
18.1.3 ASIA-PACIFIC
18.1.3.1. JAPAN
18.1.3.2. CHINA
18.1.3.3. SOUTH KOREA
18.1.3.4. BANGLADESH
18.1.3.5. AUSTRALIA
18.1.3.6. SINGAPORE
18.1.3.7. THAILAND
18.1.3.8. MALAYSIA
18.1.3.9. INDONESIA
18.1.3.10. PHILIPPINES
18.1.3.11. VIETNAM
18.1.3.12. REST OF ASIA-PACIFIC
18.1.4 SOUTH AMERICA
18.1.4.1. BRAZIL
18.1.4.2. ARGENTINA
18.1.4.3. PERU
18.1.4.4. REST OF SOUTH AMERICA
18.1.5 MIDDLE EAST AND AFRICA
18.1.5.1. SOUTH AFRICA
18.1.5.2. SAUDI ARABIA
18.1.5.3. UAE
18.1.5.4. EGYPT
18.1.5.5. KUWAIT
18.1.5.6. ISRAEL
18.1.5.7. REST OF MIDDLE EAST AND AFRICA
19 GLOBAL SMALLPOX TREATMENT MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL SMALLPOX TREATMENT MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL SMALLPOX TREATMENT MARKET, COMPANY PROFILE
21.1 BAVARIAN NORDIC
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 EMERGENT BIOSOLUTIONS INC
21.2.1 COMPANY OVERVIEW
21.2.2 REVENUE ANALYSIS
21.2.3 GEOGRAPHIC PRESENCE
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SIGA TECHNOLOGIES
21.3.1 COMPANY OVERVIEW
21.3.2 REVENUE ANALYSIS
21.3.3 GEOGRAPHIC PRESENCE
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 CHIMERIX
21.4.1 COMPANY OVERVIEW
21.4.2 REVENUE ANALYSIS
21.4.3 GEOGRAPHIC PRESENCE
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 GILEAD SCIENCES
21.5.1 COMPANY OVERVIEW
21.5.2 REVENUE ANALYSIS
21.5.3 GEOGRAPHIC PRESENCE
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 BIOFACTURA, INC.
21.6.1 COMPANY OVERVIEW
21.6.2 REVENUE ANALYSIS
21.6.3 GEOGRAPHIC PRESENCE
21.6.4 PRODUCT PORTFOLIO
21.6.5 RECENT DEVELOPMENTS
21.7 TONIX PHARMACEUTICALS HOLDING CORP.
21.7.1 COMPANY OVERVIEW
21.7.2 REVENUE ANALYSIS
21.7.3 GEOGRAPHIC PRESENCE
21.7.4 PRODUCT PORTFOLIO
21.7.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
22 RELATED REPORTS
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
